LncRNA HMGA2-AS1 promotes postoperative recurrence in non-muscle-invasive bladder cancer by sponging miR-367-3p to activate YAP1 Authors: Yingjie Wang, Zhen Nai, Jianbin Zhang Published: 2026 ABSTRACT AbstractBackgroundNon-muscle-invasive bladder cancer (NMIBC) is characterized by a high postoperative recurrence rate. LncRNAs have emerged as key regulators in cancer progression. The clinical relevance and mechanistic role of HMGA2-AS1 in NMIBC recurrence remain unclear.MethodsClinical samples contained paired adjacent and tumor tissues from 110 NMIBC patients. HMGA2-AS1 expression was examined using qRT-PCR, and its association with clinicopathological features and recurrence-free survival (RFS) was analyzed. Kaplan-Meier and Cox regression analyses were performed to evaluate prognostic value. Functional assays, including CCK-8, migration, and stemness- and epithelial–mesenchymal transition-related gene expression analyses, were conducted in RT4 and 5637 cells. RNA interaction analyses were performed using a dual-luciferase reporter assay.ResultsHMGA2-AS1 was elevated in NMIBC tissues and was closely associated with adverse clinicopathological characteristics (tumor grade and stage), and shorter RFS. HMGA2-AS1 is an independent risk factor for postoperative recurrence. Functionally, HMGA2-AS1 silencing suppressed cell proliferation, migration, stemness, and EMT in vitro. HMGA2-AS1 acted as a molecular sponge for miR-367-3p, thereby relieving repression of YAP1. Rescue experiments confirmed that inhibition of miR-367-3p or restoration of YAP1 expression reversed the influence of HMGA2-AS1 knockdown.ConclusionHMGA2-AS1 is upregulated in NMIBC. HMGA2-AS1 promotes NMIBC progression through the miR-367-3p/YAP1 axis.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12957-026-04391-7.Keywords: Non-muscle-invasive bladder cancer, Recurrence, HMGA2-AS1, miR-367-3p, YAP1 Introduction Cancer is a complex and heterogeneous group of diseases characterized by uncontrolled cell proliferation, evasion of apoptosis, sustained angiogenesis, and metastatic dissemination. Over the past decades, cancer treatment strategies have evolved substantially, transitioning from conventional approaches such as surgery, chemotherapy, and radiotherapy to more precise modalities including targeted therapy and immunotherapy [1]. Despite these advances, tumor recurrence, therapeutic resistance, and disease progression remain major clinical challenges, underscoring the need for a deeper understanding of molecular mechanisms driving cancer development and recurrence [2–4]. Bladder cancer (BC) is among the ten most common malignant tumors worldwide [5]. Owing to its complex treatment strategies and high recurrence rate, BC is regarded as one of the costliest malignancies to manage [6, 7]. Based on whether tumor cells invade the muscle layer of the bladder wall, it is classified as muscle-invasive bladder cancer (MIBC) or non-muscle-invasive bladder cancer (NMIBC) [8]. NMIBC accounts for approximately 75% of newly diagnosed BC cases and constitutes the predominant clinical subtype [9]. NMIBC exhibits a relatively indolent biological behavior. Despite continuous advances in therapies, the overall prognosis of NMIBC has shown limited improvement over the past several decades, with reported 5-year recurrence rates ranging from 31% to 78% [10]. Patients may require repeated surgical interventions, long-term intravesical chemotherapy, or immunotherapy [11]. This clinical paradox of “low mortality but high social and economic burden” highlights the urgent need to optimize prognostic and therapeutic strategies for NMIBC. Identifying novel prognostic factors independent of clinical and pathological parameters remains a key research focus. LncRNA consists of over 200 nucleotides and lacks the ability to encode peptides or proteins [12]. With the rapid advancement of genomics technologies, lncRNA has been found to play a crucial role in transcriptional and post-transcriptional regulation. LncRNA are deeply involved in tumor initiation, progression, metastasis, and therapeutic resistance [13]. HMGA2 antisense RNA 1 (HMGA2-AS1) is a lncRNA located on chromosome 12q14.3. HMGA2-AS1 is implicated in pancreatic cancer progression, thyroid cancer prognosis, and esophageal squamous cell carcinoma drug resistance [14–16]. In BC, HMGA2-AS1 has been identified as a necroptosis- and ferroptosis-related molecule and is suggested to regulate epithelial–mesenchymal transition (EMT) through a competing endogenous RNA (ceRNA) mechanism involving the Wnt signaling pathway [17, 18]. Integration of TCGA public data revealed that HMGA2-AS1 level correlates with prognosis and is upregulated in BC, implying its potential oncogenic role. The ceRNA regulatory network is a widely recognized mechanism in which lncRNAs act as molecular sponges for miRNA, thus relieving miRNA-mediated repression of downstream target genes [19]. Bioinformatics predictions indicated that HMGA2-AS1 possesses a direct binding site for miR-367-3p. miR-367-3p is known to inhibit malignant growth in the BC cell line 5637 [20]. miR-367-3p participates in urinary BC progression via ceRNA network [21]. These findings suggest that HMGA2-AS1 may promote BC development by competitively binding miR-367-3p. This study included NMIBC cases and follow-up information, measuring HMGA2-AS1 expression levels in cancerous and adjacent tissues. We analyzed HMGA2-AS1 expression and explored its associations with clinicopathological characteristics and recurrence-free survival (RFS). In vitro cellular studies explored the biological functions of HMGA2-AS1 and its effects on cancer cell growth, while identifying miR-367-3p/YAP1 as an effector molecule. This study aims to discover novel molecular targets and provide a theoretical basis for NMIBC prognosis and recurrence. Materials and methods Study subjects and tissue collection One hundred ten patients diagnosed with primary NMIBC between 2018 and 2019 and treated with transurethral resection of bladder tumor (TURBT) at Tongxiang First People’s Hospital were enrolled. Paired adjacent and NMIBC tissues (located at least 2 cm from the tumor margin) were collected intraoperatively and promptly snap-frozen in liquid nitrogen for subsequent analyses. The inclusion criteria: histopathologically confirmed NMIBC; no history of MIBC; no preoperative radiotherapy, chemotherapy, or immunotherapy; no concomitant malignancies; no previous BC recurrence; complete clinicopathological and follow-up data available. Follow-up was primarily conducted through regular outpatient visits and telephone follow-ups. Patients underwent outpatient examinations every three months during the first year after surgery, and then every six months thereafter. The follow-up duration in this study covered a period of 9 to 74 months, with a median of 40. Postoperative recurrence was observed in 47 patients. Recurrence was defined as the detection of a new bladder tumor during follow-up, confirmed by cystoscopy and histopathological examination. This study was approved by the Ethics Committee of Tongxiang First People’s Hospital, and written informed consent was obtained from all participants. Cell culture The human cell lines including normal urothelial SV-HUC-1 and tumor cell RT4 and 5637, were obtained from the ATCC (USA). SV-HUC-1 and RT4/5637 cells were maintained in F-12 K and RPMI-1640 (Gibco, USA). All media were supplemented with 10% FBS (Gibco). Cells were incubated at 37 °C in a humidified atmosphere containing 5% CO2 and were passaged every 2–3 days. Cell transfection Small interfering RNA targeting HMGA2-AS1 (si-HMGA2-AS1), miR-367-3p mimic/inhibitor, negative controls (si-NC/miR-NC), YAP1 overexpression plasmid (oe-YAP1), and empty vector control were synthesized by GenePharma (Shanghai, China). RT4 and 5637 cells were seeded (2 × 105/well in 6-well plates) and transfected upon reaching 60–70% cell confluence using Lipofectamine 3000 (Invitrogen, USA). Two independent short hairpin RNAs (shRNA #1 and shRNA #2) targeting distinct regions of HMGA2-AS1 were designed and synthesized to minimize potential off-target effects. Knockdown efficiency was assessed by qRT-PCR. shRNA #1 was used for subsequent functional experiments. The final transfection concentrations of 50 nM siRNA/miRNA mimic/inhibitor or 2 µg per well plasmid were used. qRT-PCR Total RNA was extracted using TRIzol reagent (Invitrogen). RNA concentration and purity were assessed using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, USA). For lncRNA/mRNA and miRNA detection, reverse transcription was performed using the PrimeScript RT Reagent Kit and Mir-X miRNA First-Strand Synthesis Kit (Takara, Japan). qRT-PCR was conducted using SYBR Green Master Mix (Takara) on an ABI 7500 Real-Time PCR System (Applied Biosystems, USA). he reaction system (20 µL) consisted of 10 µL SYBR Green Master Mix, 0.8 µL forward primer (10 µM), 0.8 µL reverse primer (10 µM), 2 µL cDNA template, and 6.4 µL nuclease-free water. The PCR cycling conditions were as follows: initial denaturation at 95 °C for 30 s, followed by 40 cycles of denaturation at 95 °C for 5 s and annealing/extension at 60 °C for 34 s. GAPDH and U6 served as the internal reference in the 2⁻ΔΔCt method. Primer sequences are listed in Supplementary Table S2. Dual-luciferase reporter assay The potential binding regions (HMGA2-AS1 and miR-367-3p, miR-367-3p and YAP1) were predicted using the ENCORI. Wild-type (WT) and mutant (MUT) fragments containing the predicted binding sequences were inserted into the pmirGLO vector (Promega, USA). RT4 and 5637 were seeded (1⋅105/well in 24-well plates) and co-transfected with 500 ng of reporter plasmid and 50 nM miR-mimic or miR-NC using Lipofectamine 3000. Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega, USA). Cell viability assay Transfected RT4 and 5637 cells were seeded (2⋅103/well in 96-well culture plates). At 5 time points (0, 24, 48, 72, and 96 h), 10 µL of CCK-8 (Dojindo, Japan) was added to each well, incubated for 2 h, and measured 450 nm absorbance using a microplate reader (Bio-Rad, USA). Cell migration assay 5⋅104 transfected cells suspended in serum-free medium were added to the upper of Transwell chamber (8-µm, Corning, USA), while medium containing 10% FBS was placed in the lower. After 24 h, cells on the lower surface were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet (Solarbio, China). Cells were counted under a light microscope. RNA immunoprecipitation (RIP) assay RIP assays were performed to investigate the interaction between HMGA2-AS1 and miR-367-3p using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, USA) according to the manufacturer’s instructions. RT4 and 5637 cells were harvested and lysed in RIP lysis buffer supplemented with protease and RNase inhibitors. The cell lysates were incubated with magnetic beads conjugated with anti-AGO2 antibody (Abcam, USA) or normal mouse IgG (negative control) at 4 °C overnight with gentle rotation. After immunoprecipitation, the beads were washed thoroughly, and the co-precipitated RNA was extracted using TRIzol reagent. The purified RNA was subjected to reverse transcription followed by qRT-PCR to detect the enrichment of HMGA2-AS1 and miR-367-3p. The relative enrichment levels were normalized to input RNA and compared between the AGO2 and IgG group. Western blot Protein expression was analyzed by Western blot. Total protein was extracted using RIPA lysis buffer (Beyotime, China) supplemented with protease inhibitors. Equal amounts of protein were separated by SDS-PAGE and transferred onto PVDF membranes. After blocking with 5% non-fat milk, membranes were incubated with primary antibodies against CD44, ALDH1A1, OCT4, E-cadherin, Vimentin, YAP1, and GAPDH (loading control) overnight at 4 °C, followed by incubation with HRP-conjugated secondary antibodies. Protein bands were visualized using an enhanced chemiluminescence (ECL) system. TCGA data acquisition and bioinformatic analysis Publicly available transcriptomic data for BC were obtained from TCGA via the UCSC Xena platform. RNA sequencing data were downloaded in the form of TPM values. HMGA2-AS1 expression was extracted and compared between tumor and normal tissues. Patients were stratified into high- and low-level groups stratified by the median value. Survival analysis in the TCGA cohort was performed based on overall survival (OS). Statistical analysis R 4.0.0 and GraphPad Prism 9.0 were used. All experiments were independently performed at least three times, and data are presented as the mean ± standard deviation (SD) from three biological replicates. Data normality was assessed using the Shapiro–Wilk test prior to statistical analysis. Parametric tests were applied only when the data conformed to a normal distribution. Differences between two groups were analyzed using Student’s t-test/chi-square test. One-way ANOVA followed by Bonferroni post hoc test was used for multiple group comparisons. Pearson correlation, Kaplan-Meier, Univariable cox regression were used to analyze the correlation between molecular, RFS curve and risk factors for recurrence. Prior to Cox analysis, collinearity among variables was assessed using variance inflation factors. A multivariable Cox proportional hazards model was used to construct a recurrence prediction model. Model performance was assessed using the concordance index (C-index) and time-dependent ROC curves. Internal validation was performed using bootstrap resampling. The power analysis was conducted using a medium effect size (d = 0.5), a significance level of 0.05, and a desired power of 0.85 (two-tailed). The clinical sample size included meets the requirements of the power analysis. A P value < 0.05 was statistically significant. Results HMGA2-AS1 is enhanced in NMIBC and predicts postoperative recurrence HMGA2-AS1 expression was increased in NMIBC tumor tissues (P < 0.05, Fig. 1A). Consistent results were observed in TCGA-BLCA datasets, confirming elevated HMGA2-AS1 expression in BC (P < 0.05, Figure S1). Based on the HMGA2-AS1 median abundance, cases were stratified into high and low groups. High HMGA2-AS1 was linked to more aggressive tumor grade (P = 0.035) and advanced tumor stage (P = 0.007), while no associations were observed with age, sex, tumor size, or tumor multiplicity (Table 1). HMGA2-AS1 is upregulated in non-muscle-invasive bladder cancer (NMIBC) and recurrence-free survival (RFS). A Relative expression of HMGA2-AS1 in NMIBC tumor and adjacent non-tumor tissues (n = 110). B Univariable cox regression analyses of RFS. C Kaplan–Meier analysis of recurrence-free survival in NMIBC patients stratified by HMGA2-AS1 expression. D Relative expression of HMGA2-AS1 in SV-HUC-1, RT4, and 5637 cells (n = 5). Statistical significance was analyzed using Student’s t-test or one-way ANOVA where appropriate. ***P < 0.001 Table 1Correlation between HMGA2-AS1 expression and clinical characteristics of non-muscle-invasive bladder cancer patientsParametersHigh (n = 55)Low (n = 55)P-valueAge0.565 > 602723 <= 602832Sex0.817 Female1113 Male4442Number of tumor lesions0.231 Single3239 Multiple2316Tumor grade0.035 Low grade2335 High grade3220Tumor Size0.328 < 3 cm2733 >= 3 cm2822Tumor stage0.007 Ta2035 T13520 Correlation between HMGA2-AS1 expression and clinical characteristics of non-muscle-invasive bladder cancer patients Univariable Cox regression analysis further demonstrated that HMGA2-AS1 expression (HR = 3.75, 95% CI: 1.59–5.46), along with tumor number, grade, size, and stage, is an independent risk factor for NMIBC postoperative recurrence (P < 0.05, Fig. 1B). Patients with high HMGA2-AS1 had shorter RFS (P = 0.034; Fig. 1C). HMGA2-AS1 expression was markedly higher in RT4 and 5637 (P < 0.05, Fig. 1D). To further evaluate the predictive utility of HMGA2-AS1, a recurrence prediction model was constructed using multivariable Cox regression incorporating HMGA2-AS1 expression and clinicopathological variables (Table S1). A nomogram was subsequently developed to estimate 1-, 3-, and 5-year recurrence probabilities. The model demonstrated an overall C-index of 0.73 (95% CI: 0.56–0.85). Internal validation using bootstrap resampling yielded a C-index of 0.698. Time-dependent ROC analysis showed that the AUC values for predicting 1-, 3-, and 5-year recurrence were all approximately 0.80 (Figure S2). HMGA2-AS1 promotes proliferation, migration, stemness, and EMT in RT4 and 5637 To further exclude potential off-target effects, two independent shRNAs targeting HMGA2-AS1 were employed. Both shRNA #1 and shRNA #2 significantly reduced HMGA2-AS1 expression and inhibited cell proliferation in RT4 and 5637 cells (Figure S3). HMGA2-AS1 knockdown effectively decreased HMGA2-AS1 expression (P < 0.05, Fig. 2A). siRNA-mediated knockdown of HMGA2-AS1 decreased cell viability in both RT4 and 5637 (P < 0.05, Fig. 2B-C). HMGA2-AS1 silencing inhibited cell migration (P < 0.05, Fig. 2D). Knockdown of HMGA2-AS1 reduced the mRNA expression and protein levels of stemness-related markers (CD44, ALDH1A1, and OCT4), increased E-cadherin, and decreased Vimentin in both cell lines (P < 0.05, Fig. 2E-G). HMGA2-AS1 knockdown suppresses proliferation, migration, stemness, and EMT in bladder cancer cells (n = 3). A qRT-PCR analysis of HMGA2-AS1 expression after siRNA transfection. B-C CCK-8 assays assessing cell viability in RT4 and 5637 cells. D Transwell assays evaluating cell migration. E-F Relative expression of stemness- and EMT-related genes in RT4 and 5637 cells. G-H Western blot analysis of protein expression in RT4 and 5637 cells following HMGA2-AS1 knockdown (n = 3). Statistical significance was analyzed using one-way ANOVA followed by Bonferroni post hoc test. **P < 0.01, ***P < 0.001 HMGA2-AS1 functions as a ceRNA by sponging miR-367-3p miR-367-3p abundance declined in NMIBC tissues and cells (P < 0.05, Fig. 3A-B). miR-367-3p expression is a prognostic factor for NMIBC recurrence (P < 0.05, Fig. 1B). miR-mimic reduced luciferase signal of the WT HMGA2-AS1 reporter in two cell lines, but not the mutant construct (P < 0.05, Fig. 3C). Both HMGA2-AS1 and miR-367-3p were significantly enriched in the AGO2 immunoprecipitated complex compared with the IgG control (P < 0.05, Fig. 3D). A significant inverse relationship between HMGA2-AS1 and miR-367-3p in NMIBC (R = -0.715, P < 0.001, Fig. 3E). HMGA2-AS1 functions as a ceRNA for miR-367-3p in bladder cancer cells. A miR-367-3p expression in non-muscle-invasive bladder cancer tissues (n = 110). B miR-367-3p expression in bladder cancer cell lines (n = 5). C Dual-luciferase reporter assays validating the interaction between HMGA2-AS1 and miR-367-3p (n = 3). D AGO2-RIP assay validating HMGA2-AS1/miR-367-3p interaction (n = 3). E Pearson correlation between HMGA2-AS1 and miR-367-3p expression (n = 110). F miR-367-3p expression after HMGA2-AS1 knockdown and miR-367-3p inhibition (n = 3). G-I CCK-8 assays (G-H) and Transwell migration (I) after treatment with si-HMGA2-AS1 knockdown and miR-inhibitor (n = 3). J-K Expression of stemness- and EMT-related genes after co-transfection (n = 3). L-M Protein levels of stemness- and EMT-related genes after co-transfection (n = 3). Statistical significance was analyzed using one-way ANOVA followed by Bonferroni post hoc test. P < 0.05, **P < 0.01, ***P < 0.001 HMGA2-AS1 knockdown significantly enhanced miR-367-3p expression, whereas miR-inhibitor partially reversed this effect in RT4 and 5637 (Fig. 3F). Functionally, inhibition of miR-367-3p partially rescued the repressive effects of HMGA2-AS1 knockdown on cell behavior (P < 0.05, Fig. 3G-I). miR-367-3p inhibition reversed the alterations in stemness- and EMT-related levels induced by HMGA2-AS1 silencing (P < 0.05, Fig. 3J-M). YAP1 is a direct target of HMGA2-AS1/miR-367-3p Axis YAP1 was highly expressed in NMIBC tissues (P < 0.05, Fig. 4A). YAP1 was negatively linked to miR-367-3p levels (R = -0.602, P < 0.001, Fig. 4B). YAP1 was a direct downstream target of miR-367-3p through bioinformatic prediction and dual-luciferase reporter assays (P < 0.05, Fig. 4C). si-HMGA2-AS1 reduced YAP1 expression, while YAP1 overexpression reversed this effect (P < 0.05, Fig. 4D-E). Rescue experiments showed that YAP1 overexpression significantly counteracted the attenuating effects of HMGA2-AS1 knockdown on cell proliferation and migration (P < 0.05, Fig. 4F-H). In RT4 and 5637 cells, restoration of YAP1 expression also reversed the alterations in stemness characteristics and EMT-related gene expression induced by HMGA2-AS1 knockdown (P < 0.05, Fig. 4I-L). HMGA2-AS1 regulates NMIBC progression via the miR-367-3p/YAP1 axis. A YAP1 expression in adjacent and non-muscle-invasive bladder cancer tissues (n = 110). B Correlation between miR-367-3p and YAP1 expression (n = 110). C Dual-luciferase reporter assays validating miR-367-3p targeting of YAP1 (n = 3). D-E YAP levels after HMGA2-AS1 knockdown and YAP1 overexpression (n = 3). F-H CCK-8 proliferation (F-G) and transwell migration (H) assays after co-transfection (n = 3). I-L Stemness- and EMT-related mRNA (I-J) expression and protein analysis (K-L) treatment with si-HMGA2-AS1 and oe-YAP1 (n = 3). Statistical significance was analyzed using one-way ANOVA followed by Bonferroni post hoc test. P < 0.05, **P < 0.01, ***P < 0.001 Discussion Over 70% of BC are confined to the mucosa or submucosa and are classified as NMIBC [9]. In the collected cohort, women constituted less than a quarter of the population. This aligns with epidemiological studies. Male BC incidence is significantly higher than in females, approximately 3 to 4 times greater [22]. This sex disparity may be attributed to differences in exposure to risk factors such as smoking, alcohol consumption, and occupational carcinogens. NMIBC is characterized by high postoperative recurrence rates [10]. Identifying molecular drivers of recurrence and elucidating their underlying mechanisms are critical for improving risk stratification and treatment decisions. Among the included cases, over 40% of cases exhibited recurrence. BC recurrence is driven by multiple factors involving tumor cell implantation, cancer stem cell (CSC) persistence, alterations in the bladder microenvironment, and cumulative genetic and molecular changes [23, 24]. HMGA2-AS1 expression was higher in tumor tissues. Patients with high HMGA2-AS1 levels exhibited poorer RFS, suggesting HMGA2-AS1 may be a key driver of tumor recurrence and a potential prognostic marker. Low-grade and high-grade NMIBC differ substantially in cellular morphology and biological behavior. High-grade NMIBC displays poor differentiation, disorganized cellular arrangement, and high invasive potential, associated with increased recurrence and progression risks [25]. The higher proportion of high-grade tumors observed in the HMGA2-AS1 high-expression group suggests that HMGA2-AS1 may be involved in tumor dedifferentiation and malignant transformation. Tumor stage is a critical determinant of NMIBC recurrence. The T stage reflects the depth of tumor invasion into the bladder wall, with T1 tumors breaching the basement membrane and invading the lamina propria. Such tumors exhibit biological behavior closer to early invasive carcinoma [26]. The association between HMGA2-AS1 overexpression and T1 stage suggests that abnormal HMGA2-AS1 level may represent a key molecular event in tumor progression from superficial to deeper layers. Consistent with conventional clinical-pathological parameters, Cox analysis confirms HMGA2-AS1 as an independent predictor of postoperative recurrence. These findings suggest HMGA2-AS1 may actively participate in mechanisms that “drive” tumors toward higher-grade, more aggressive biological behavior, positioning it as a key molecular driver of recurrence. Functional experiments supported the clinical observations. RT4 and 5637 cell lines were used as in vitro models to investigate the functional role of HMGA2-AS1. These cell lines represent distinct biological characteristics of bladder cancer, with RT4 derived from low-grade, well-differentiated tumors and 5637 exhibiting more aggressive features [27, 28] The consistent findings observed across both models support the robustness of HMGA2-AS1-mediated effects. Tumor cell proliferation and migration constitute the direct cellular biological basis driving recurrence. Proliferation determines tumor growth rate and the capacity for postoperative residual cell expansion, dictating the likelihood of visible recurrence foci forming [29]. Migration reflects the capacity of malignant cells to spread along the bladder mucosal surface and contributes to implantation-related recurrence [30]. Silencing HMGA2-AS1 suppressed both proliferation and migration, indicating that HMGA2-AS1 may promote NMIBC recurrence by simultaneously enhancing tumor growth and dissemination. CSCs possess self-renewal capacity, driving long-term recurrence. OCT4 is a core stemness transcription factor, while CD44 and ALDH1A1 serve as BC CSC markers [31]. E-cadherin loss represents a key initiating event of EMT and Vimentin upregulation reflects enhanced migratory capacity [32]. HMGA2-AS1 knockdown altered the expression of stemness- and EMT-related markers, suggesting that HMGA2-AS1 may activate EMT programs and reinforce CSC properties, thereby functioning as an oncogenic driver of NMIBC recurrence. It should be noted that established cell lines may not fully capture the molecular and phenotypic heterogeneity of NMIBC in patients. In particular, differences in HMGA2-AS1 expression between these cell lines may not directly reflect the full spectrum of expression patterns observed in clinical samples. Therefore, the results should be interpreted with caution and further validation in additional models. Mechanistically, HMGA2-AS1 directly binds to miR-367-3p, acting as a molecular sponge to reduce its availability. Expression level detection supports a functional antagonistic relationship between HMGA2-AS1 and miR-367-3p. miR-367-3p exerts tumor-suppressing influence not only in BC by influencing cellular functions [20]. It also serves as a potential suppressor in several other malignancies, including prostate, cervical, and gastric cancers [33–35]. miR-367-3p inhibitor partly abrogated the anti-suppressive activity induced by HMGA2-AS1 knockdown, indicating that miR-367-3p is a critical mediator of HMGA2-AS1 function. YAP1, a central oncogenic transcriptional co-activator, integrates diverse upstream signals to promote tumor cell proliferation, stemness maintenance, EMT, metastasis, and therapeutic resistance [36]. YAP1 contributes to BC cell proliferation and invasion and regulates EMT-related gene expression [37]. YAP1 signaling has been implicated in sustaining cancer stem cell properties and shaping an immunosuppressive tumor microenvironment in urothelial BC [38]. Our data revealed elevated YAP1 expression in NMIBC tissues. Functional rescue assays confirmed that YAP1 mitigated the repressive effects of HMGA2-AS1 silencing on oncogenic properties. YAP1 exerts its oncogenic functions primarily through interaction with TEAD transcription factors to regulate downstream target genes, such as CTGF and CYR61 [39]. In this study, we did not directly assess the activation status of canonical Hippo–TEAD signaling or the expression of downstream transcriptional targets. Therefore, while our findings support a functional role for YAP1, they do not fully establish the involvement of canonical Hippo pathway activation. YAP1 activity in cancer is regulated at multiple levels beyond transcriptional control, including post-translational modifications, subcellular localization, and genetic alterations. Alterations in YAP1 mutation status have been reported to influence its functional activity in tumor cells, suggesting that diverse regulatory mechanisms may converge on YAP1 signaling [40]. These findings highlight that the regulatory landscape of YAP1 is multifaceted and context-dependent. We identified HMGA2-AS1 as a previously uncharacterized lncRNA in NMIBC and demonstrated its significant association with recurrence-free survival, highlighting its potential clinical relevance. Mechanistically, we uncovered a novel HMGA2-AS1/miR-367-3p/YAP1 regulatory axis, expanding the repertoire of ceRNA networks implicated in NMIBC progression. While YAP1 signaling has been implicated in tumor progression, its regulation via miR-367-3p in the context of HMGA2-AS1 has not been previously reported. These findings distinguish HMGA2-AS1 from previously reported lncRNAs by linking it to recurrence prediction and identifying a novel regulatory pathway, thereby providing new insights into NMIBC pathogenesis and potential therapeutic targets. LncRNAs have been widely recognized as key regulators in cancer, with roles spanning diagnosis, prognosis, and therapeutic targeting across multiple malignancies. Emerging evidence suggests that single-axis regulatory models, while mechanistically informative, may not fully capture the multilayered nature of tumor biology and typically require further validation across diverse regulatory contexts before clinical translation. In this regard, the HMGA2-AS1/miR-367-3p/YAP1 axis identified in this study should be interpreted as a contributory mechanism rather than a comprehensive model of NMIBC progression. Despite these strengths, several limitations should be acknowledged. This study lacks external validation using independent cohorts, which may limit the generalizability and robustness of the proposed prediction model. Future studies incorporating multicenter datasets are warranted to further validate its clinical applicability. Although functional experiments were performed in two bladder cancer cell lines representing different pathological features of NMIBC, the findings may still be influenced by cell line-specific characteristics. The absence of additional models, such as primary tumor cells or organoid systems, may limit the generalizability of the results. Future studies incorporating diverse in vitro and in vivo models are warranted to further validate the biological role of HMGA2-AS1. In this study, TCGA-BLCA data were used to support the expression pattern and potential prognostic relevance of HMGA2-AS1. Given that the case composition of the TCGA cohort is not clearly defined—while the present study focuses on NMIBC—this discrepancy may limit direct comparability and introduce potential bias. TCGA findings should be interpreted as supportive. Analyses based on bulk transcriptomic datasets are subject to technical and biological biases, including tumor heterogeneity and data processing variability, which may influence gene expression estimates. Previous studies have highlighted these challenges in cancer transcriptomic research [41, 42]. Accordingly, TCGA results in this study are presented as complementary evidence, and further validation in NMIBC-specific cohorts is warranted. This study primarily focuses on the downstream functional mechanisms of the HMGA2-AS1/miR-367-3p axis and does not comprehensively explore the upstream drivers of HMGA2-AS1 dysregulation in tumors. Future investigations will examine whether its expression is influenced by genomic copy number alterations, promoter methylation, or inflammatory signaling within the tumor microenvironment, thereby placing this regulatory axis within a broader framework of tumorigenesis and progression. Conclusion HMGA2-AS1 is upregulated in NMIBC and is significantly associated with postoperative recurrence. Functionally, HMGA2-AS1 promotes bladder cancer cell proliferation, migration, stemness, and EMT by regulating the miR-367-3p/YAP1 axis. Further external validation is warranted to confirm its clinical applicability. Supplementary Information Supplementary Material 1: Figure S1. Validation of HMGA2-AS1 expression and prognostic value using TCGA datasets. HMGA2-AS1 expression in bladder cancer tissues and Kaplan–Meier survival analysis based on public cohort data. Supplementary Material 2: Figure S2. Development of a prognostic scoring model for Bladder cancer. Nomogram chart (A) and receiver operating characteristic curve (B) for prognostic prediction model based on Cox regression. Supplementary Material 3: Figure S3. Validation of HMGA2-AS1 knockdown efficiency and specificity. (A) Relative expression of HMGA2-AS1 after transfection with two independent shRNAs in two cells. (B) CCK-8 assay showing cell proliferation following HMGA2-AS1 knockdown. ***P < 0.001. Supplementary Material 4. Supplementary Material 5. Acknowledgements Not applicable. Clinical trial number Not applicable. Authors' contributions All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Z N, YJ W and JB Z. The first draft of the manuscript was written by YJ W and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Funding The authors did not receive support from any organization for the submitted work. Data availability All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author. Declarations Ethics approval and consent to participate The authors state that they have obtained Tongxiang First People’s Hospital review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved. Consent for publication All patients provided written informed consent. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Yingjie Wang and Zhen Nai contributed equally to the text. References Associated Data Supplementary Materials Supplementary Material 1: Figure S1. Validation of HMGA2-AS1 expression and prognostic value using TCGA datasets. HMGA2-AS1 expression in bladder cancer tissues and Kaplan–Meier survival analysis based on public cohort data. Supplementary Material 2: Figure S2. Development of a prognostic scoring model for Bladder cancer. Nomogram chart (A) and receiver operating characteristic curve (B) for prognostic prediction model based on Cox regression. Supplementary Material 3: Figure S3. Validation of HMGA2-AS1 knockdown efficiency and specificity. (A) Relative expression of HMGA2-AS1 after transfection with two independent shRNAs in two cells. (B) CCK-8 assay showing cell proliferation following HMGA2-AS1 knockdown. ***P < 0.001. Supplementary Material 4. Supplementary Material 5. Data Availability Statement All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.